Organogenesis Holdings Inc. (ORGO): R&D Expense
$44.54M
Year ended 2025-12-31
$56.97M
Trailing 12 months to 2026-06-30
+3.9%
3-year compound annual growth
+17.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $44.54M | -11.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $50.27M | +13.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $44.38M | +11.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $39.76M | +29.3% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $30.74M | +53.1% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $20.09M | +35.7% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $14.80M | +37.8% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $10.74M | +18.5% | 2021-03-16, From 2018-01-01 |
| 2017-12-31 | $9.06M | +44.4% | 2020-03-09, From 2017-01-01 |
| 2016-12-31 | $6.28M | n/a | 2019-03-18, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $44.54M | -11.4% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $148.29M | -30.1% |
| Insmed Inc (INSM) | 2025-12-31 | $771.09M | +28.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $124.03M | +17.9% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $186.18M | +32.4% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $160.22M | +69.9% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $451.95M | -10.8% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $183.28M | -2.0% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $206.01M | -5.3% |
Compare ORGO, HCM, INSM, OPK side by side · Screen every company in Pharmaceutical Preparations ↗